Completed PHASE2 INTERVENTIONAL 2-arm NCT05127421

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

A Phase 2, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Sponsor: Incyte Corporation

Conditions Atopic Dermatitis

Interventions Ruxolitinib cream Vehicle

Updated 11 times since 2021 Last updated: Aug 14, 2024 Started: Nov 10, 2021 Primary completion: Aug 3, 2023 Completion: Sep 29, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2023 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE2
Aug 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting

▶ Show 6 earlier versions

Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE2
Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Culver City, United States